Detection of Prostate Cancer: A Review

Abstract

Prostate cancer is the most commonly diagnosed non-cutaneous cancer in men. Prostate-specific antigen (PSA) is the biomarker used for the screening of prostate cancer and other prostate-related problems. Not only the genetic factors are involved dietary factors, environmental factors but also responsible for the development of prostate cancer. Risk factors such as family history, age, chemical exposure, infection, and smoking are at the peak point for the development of prostate disease. Advanced age is one of the main risk factors. Radical prostatectomy is the most common therapy for small group of patients with high-grade tumors. Early screening of PSA reduces the incidence rate of prostate cancer. Mostly prostate abnormalities are seen in among male patients above the age of 50 years or older. In worldwide population, the epidemiology of prostate cancer is high in western countries and less in Asian countries.

Consummated Review on Prostatitis

“…It results in inhibition of the growth of the specific hormone, proves and shows that luteinizing hormone-releasing hormone agonists promote tumors (such as prostatic tumors). Examples are buserelin, leuprolide, and goserelin [75]. Antiandrogens exert its action by inhibiting androgen uptake and by inhibiting nuclear binding of androgen to the androgen receptors on prostatic cells such as flutamide and nilutamide.…”

Cardiovascular Risk Associated With Androgen Deprivation Therapy in Advanced Prostate Cancer

“…Althogh prostate cancer is a global health problem, it is a common cancer in men and on the Asian continent it is only now found to be increasing rapidly [1][2][3][4]. Changing lifestyles may remain one responsible factor for this [5].…”